Connect with us

BUSINESS

Rushnet Inc (OTCMKTS: RSHN) and Purchase Target Report Record Income of an Estimated $1.56 Million

Published

on

RushNet Inc (OTCMKTS: RSHN) and its Purchase target have reported that in the Second Quarter of the current financial year that they have clocked a record income of an estimated $1.56M. 

Highlights of Second Quarter

  • Quarter 2 saw record income at an appraised $1.56M versus a stretch objective of $1.4M. It is an upsurge QOQ of around $300,000 or 23.91%
  • The company outperformed its stretch target by 11.43%
  • The Gross Profit for the Second Quarter was appraised at $1.256M versus Gross Profit in Quarter 1 of $1.001M. It is a surge QOQ of about $255,000 or 25.47%.
  • Company to post an assessed profit in Quarter 2 of $226,789 versus Quarter 1 profit of $40,737. It is an assessed surge QOQ of $186,052 or 456.72%
  • The company handled a record number of samples in Quarter 2 at a projected 6,842 versus Quarter 1 at 6,488. It is a surge of 354 specimens or 5.46%.
  • The company also set a new yardstick in May 2021 of around $530,000 in Monthly Income.

RushNet to offshoot heliosDX and soon afterward herself

RushNet shall offshoot heliosDX, and soon afterward, RushNet herself will spinoff with its current possessions. Each derivative unit will become a visibly traded unit. The heliosDX offshoot will reward RushNet, Inc. stockholders with a dividend of up to 12 shares (one share downright and 11 rights to buy a share at a markdown at the heliosDX price) of heliosDX for every 1000 shares they own, as of the ex-dividend date, to be recognized soon.

heliosDX will be domiciled in Georgia, where the diagnostics business is headquartered. The procedure will include heliosDX filing a Form 1-A, Tier 2, to succeed all shares distributed in quest of this offshoot, thus giving RushNet stockholders the chance to buy extra shares at a markdown to the market price. In addition, the incomes from the submission will be used to close formerly announced directed purchase candidates.

After finishing both incidentals, Ashley Sweat will continue as the Chairman and CEO of RushNet, Inc. RushNet Inc. will purchase Grandeza Healthcare Consultants, presently majority possessed by Ashley Sweat. Grandeza is in its foundational year and will attain more than $1,000,000 in income this year and be money-making. It is the ideal situation for Grandeza as the business has room to develop, and RushNet, Inc. is the perfect vehicle for such development.

[optin-monster-shortcode id="lt2ftjs5qhrst1pzmmap"] *Past performance is not a predictor of future results. All investing involves risk of loss and individual investments may vary. The examples provided may not be representative of typical results. Your capital is at risk when you invest – you can lose some or all of your money. Never risk more than you can afford to lose.By submitting your information you agree to the terms of our Privacy Policy • Cancel Newsletter Any Time.This is a FREE service from Finacials Trend. Signing up for our FREE daily e-letter also entitles you to receive this report. We will NOT share your email address with anyone.
Continue Reading
Advertisement
Click to comment

Leave a Reply

Your email address will not be published. Required fields are marked *

BUSINESS

Can B Corp (OTCMKTS: CANB) Signs Partnership To Market CBD Products and Releases Q1 2021 Results

Published

on

Can B Corp (OTCMKTS: CANB) has entered a partnership with a company comprising World Champion Action Sports Athletes and Professional Hollywood Stuntmen to market the Can B Corp’s existing select CBD products and launch a new CBD brand at the end of the summer. 

Can B enters a partnership for its CBD products 

Notably, the Professional Hollywood Stuntmen group lists film credits include The Hunger Games, Breaking bad, Ant-Man, Twilight Saga, Fast & Furious 7, Jason Bourne, Mulan, The Expendables Better Call Saul, and others. Additionally, the group will commence marketing Can B Corp’s CBD products Slave 100& 200 mg and CryoGel Gold 500 mg. 

Can B CEO Marco Alfonsi said, “This is a really exciting new partnership for our Company, as it provides a new untapped distribution channel for our manufacturing and production, which remains under-utilized. Our Lacey, Washington facility continues to have an excess capacity which we can use for new private label customers. This group of Professional Hollywood Stuntmen and World Champion Action Sports Athletes has great exposure and a wide social media following, which they will utilize to market and advertise the CBD products.”

Can B’s Q1 2021 revenue dropped 46%

Recently the company announced its Q1 2021, during which revenue was $306,940, a 46% YoY decline. The drop resulted from the pandemic’s impact leading to the halting of elective surgeries, which is the primary medical device revenue source for the company. Additionally, some distributors lost clients because of business closure impacting the company’s overall revenue. During the quarter, the company closed the acquisition of talent and assets from Botanical Biotech. 

Alfonsi stated, “While we experienced a decline in our revenue due to Covid-19’s negative impact on markets we serve in elective surgeries and lost clients due to business closings of certain distributors, we have taken the time to maintain and strengthen our vertically integrated platform.”

[optin-monster-shortcode id="lt2ftjs5qhrst1pzmmap"] *Past performance is not a predictor of future results. All investing involves risk of loss and individual investments may vary. The examples provided may not be representative of typical results. Your capital is at risk when you invest – you can lose some or all of your money. Never risk more than you can afford to lose.By submitting your information you agree to the terms of our Privacy Policy • Cancel Newsletter Any Time.This is a FREE service from Finacials Trend. Signing up for our FREE daily e-letter also entitles you to receive this report. We will NOT share your email address with anyone.
Continue Reading

BUSINESS

The Valens Company Inc. (OTCMKTS: VLNCF) Signs Production and Distribution Deal with Harvest One

Published

on

The Valens Company Inc. (OTCMKTS: VLNCF) has entered a two-year deal with Harvest One Cannabis Inc. as a provincial partner and white label manufacturer for cannabis-infused tropicals for LivReleif, its leading brand. 

Harvest One launched LivRelief in 2020

Harvest One is a global marijuana infusion CPG operator that distributes high-quality self-care and wellness products, and it launched its leading cannabis-infused LivRelife products portfolio last year. Notably, since last year the products line has grown to be the number one cannabis-infused topicals selling brand in Ontario. 

LivRelief is created through natural ingredients for deep penetration utilizing a novel transdermal delivery system that allows CBD to reach target areas. It is a growing cannabis-infused topical creams line that is available in their formats, including 1:1 formulation with 125mg THC and CBD, CBD only formulation with 250mg of CBD, and the recently launched extra strength CBD cream containing 750mg CBD. Currently, the products are available nationally through Medical Cannabis by Shoppers and at various private and provincial retailers. 

Harvest One and Valens to expand distribution of LiRRelief

Through the partnership, The Valens and Harvest One will expand distribution and enhance customer awareness and brand loyalty nationwide. The first product shipments from Valens’ facilities will begin in fiscal Q4 2021. 

Valens CEO Tyler Robson said, “The LivRelief cannabis-infused topical brand has established itself as a premium and reliable provider of cannabis-infused topicals with a leading-edge proprietary transdermal delivery system that took years of research, innovation, and dedication to develop. We are proud to manufacture these top-selling creams in partnership with Harvest One and provide both new and experienced consumers the comfort to engage with cannabis-infused topicals. Valens already manufactures the number one selling bath product in Ontario3 and now adds the number one selling cannabis-infused topical brand to its portfolio, making it a clear leader in both the topicals and health and wellness verticals in Canada.”

[optin-monster-shortcode id="lt2ftjs5qhrst1pzmmap"] *Past performance is not a predictor of future results. All investing involves risk of loss and individual investments may vary. The examples provided may not be representative of typical results. Your capital is at risk when you invest – you can lose some or all of your money. Never risk more than you can afford to lose.By submitting your information you agree to the terms of our Privacy Policy • Cancel Newsletter Any Time.This is a FREE service from Finacials Trend. Signing up for our FREE daily e-letter also entitles you to receive this report. We will NOT share your email address with anyone.
Continue Reading

BUSINESS

Vivo Cannabis Inc. (OTCMKTS: VVCIF) Receives Permit to Import Dried Medical Cannabis to Germany

Published

on

Vivo Cannabis Inc. (OTCMKTS: VVCIF) has announced that it’s EU-GMP/GDP licensed affiliate Beacon Medical Germany GmbH has been granted an import permit by Germany’s Federal Institute for Drugs and Medical Devices.  With the grant to the permit, the company can now import Canadian grown dried medical cannabis flower from Vivo’s ABcann Medicinal subsidiary’s GMP-certified Napanee, Ontario site into the EU. 

Vivo taking steps to commercialize the product in Europe

Vivo holds cannabis licenses under the Cannabis ACT through its subsidiaries ABcann Medicinals Inc. and Canna Farms Limited. 

Canna Farms Co-founder and VIVO CEO Ray Laflamme said, “We are making great strides towards our first commercialization of product in Europe. As a leader in medical cannabis in Canada and Australia, we are delighted by the opportunity to bring our Beacon Medical™ products to market and support the increasing demand from Germany’s more than 130,000 medical cannabis clients.”

The import permit received is issued on a shipment-by shipment basis. After receiving the export approval from Health Canada, the company will ship its first product in late Q3 or ear Q4, which will be offered under the Beacon medical brand. 

Vivo Cannabis launched Canna Farms Brick Hash

The company recently launched Canna Farms Brick Hash, a high-quality, solventless, all-natural concentrate consumed as an edible through inhalation. Hashish is produced through resin extraction from cannabis and converting it into a solid form. Canna Farms Brick Hash is produced using modern tech and solvent-free extraction at the Hope facility. The novel process starts with blended Kief input from premium dried marijuana. Next, the hashish is slow-cooked and pressed, under pressure, cured, and wrapped in parchment to perfection for 30 days.

Laflamme said, “Our team has worked hard to perfect our process, and we’re very proud to bring to market another premium craft medical product catered to clients needing higher potency dosing.”

[optin-monster-shortcode id="lt2ftjs5qhrst1pzmmap"] *Past performance is not a predictor of future results. All investing involves risk of loss and individual investments may vary. The examples provided may not be representative of typical results. Your capital is at risk when you invest – you can lose some or all of your money. Never risk more than you can afford to lose.By submitting your information you agree to the terms of our Privacy Policy • Cancel Newsletter Any Time.This is a FREE service from Finacials Trend. Signing up for our FREE daily e-letter also entitles you to receive this report. We will NOT share your email address with anyone.
Continue Reading

Trending Stories